• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia

Trendingnow

1

Social Security's 2032 deadline puts a 22% cut on the table — but Washington has way less room to negotiate than 1983

2

CEO of $20 billion AI firm Perplexity says the secret to success is ‘sleeping with that fear’ that your competitor will steal your idea

3

Boomers actually do hold most of the wealth and power. So why do they call it 'whiny' to point that out?

1

Social Security's 2032 deadline puts a 22% cut on the table — but Washington has way less room to negotiate than 1983

2

CEO of $20 billion AI firm Perplexity says the secret to success is ‘sleeping with that fear’ that your competitor will steal your idea

3

Boomers actually do hold most of the wealth and power. So why do they call it 'whiny' to point that out?
NewslettersBrainstorm Health

Which Medicines Have Transformed Drug Development in the Past Decade?

By
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
By
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
November 22, 2019, 5:37 PM ET

This is the web version of Brainstorm Health Daily, Fortune’s daily newsletter on the top health care news. To get it delivered daily to your in-box, sign up here.

Happy Friday, readers!

I have a selfish request of all of you this evening.

If you have any thoughts about which drugs, medicines, therapies, procedures, etc have served the American (and global) public best over the past decade, I’d love to read what you have to say.

I have a few ideas. Truvada and PrEP (those treatments that can essentially prevent HIV transmission) come to mind. Cancer immunotheraphy, new gene therapies, and so many other drugs are clear contenders.

But I want to hear your expert opinions. I’m sure there are plenty of things I’m missing – a rare disease drug I’ve never heard of, or a therapy for condition I never knew existed. Please weigh in.

Read on for the day’s news, and have a wonderful weekend.

Sy Mukherjee
sayak.mukherjee@fortune.com
@the_sy_guy

DIGITAL HEALTH

ViiV, NIH team up on HIV antibodies. ViiV Healthcare, the joint project between  GlaxoSmithKline and Pfizer, is teaming up with the National Institutes of Health to tackle HIV with a new kind of therapy. The experimental "broadly neutralizing antibody" could potentially slash costs (and be an effective medicine against) the HIV-1 strain; there is plenty of work to be done, and the proof is in the pudding. (Endpoints News)

THE BIG PICTURE

Flu season is picking up. Get your shots. Flu season is already upon us, according to the CDC (not exactly surprising given that it can last all the way up to early summer). But it's already hit about 30 states, and it could be a brutal season. As the mantra goes: Get your shots (if not for yourself, at the very least for others). (NBC News)

REQUIRED READING

Vaping Fight Hits Fever Pitch With White House Meeting, by Bloomberg

The 27 Best Stocks to Buy for 2020, by Rey Mashayekhi & Anne Sraders

AT&T Announces Its 5G Rollout, by Aaron Pressman

Sign up for other Fortune newsletters.

IF YOU LIKE THIS EMAIL...

Share today’s Brainstorm Health with a friend.

Did someone share this with you? Sign up here. For previous editions, click here.

For even more, check out raceAhead, Fortune's daily newsletter on culture in corporate America. Sign up here.

About the Author
By Sy Mukherjee
See full bioRight Arrow Button Icon

Latest in Newsletters

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in Newsletters

SpaceX just made IPO history. Gwynne Shotwell made it possible
NewslettersMPW Daily
SpaceX just made IPO history. Gwynne Shotwell made it possible
By Emma HinchliffeJune 12, 2026
3 days ago
Mo Jomaa of CapitalG, Nizar Tarhuni of PitchBook, and Hans Tung of Notable Capital at Fortune Brainstorm Tech 2026 in Aspen, Colorado. (Photo: Stuart Isett/Fortune)
NewslettersFortune Tech
The SpaceX IPO is not the market savior it seems
By Andrew NuscaJune 12, 2026
3 days ago
How Elon Musk sold a $1.77 trillion dream—and what other CEOs can learn from the SpaceX IPO
NewslettersCEO Daily
How Elon Musk sold a $1.77 trillion dream—and what other CEOs can learn from the SpaceX IPO
By Diane BradyJune 12, 2026
3 days ago
Why is it so hard to get ROI from AI? Because building from first principles isn’t easy
NewslettersEye on AI
Why is it so hard to get ROI from AI? Because building from first principles isn’t easy
By Jeremy KahnJune 11, 2026
3 days ago
Bridgit Mendler, co-founder and CEO of Northwood, at Fortune Brainstorm Tech 2026 in Aspen, Colorado. (Photo: Stuart Isett/Fortune)
NewslettersMPW Daily
How Hollywood trained Bridgit Mendler for life as a space founder
By Emma HinchliffeJune 11, 2026
4 days ago
Chevron’s CFO on why finance chiefs are defining AI’s business value
NewslettersCFO Daily
Chevron’s CFO on why finance chiefs are defining AI’s business value
By Sheryl EstradaJune 11, 2026
4 days ago

Most Popular

Social Security's 2032 deadline puts a 22% cut on the table — but Washington has way less room to negotiate than 1983
Personal Finance
Social Security's 2032 deadline puts a 22% cut on the table — but Washington has way less room to negotiate than 1983
By John W. Diamond and The ConversationJune 12, 2026
3 days ago
CEO of $20 billion AI firm Perplexity says the secret to success is ‘sleeping with that fear’ that your competitor will steal your idea
Success
CEO of $20 billion AI firm Perplexity says the secret to success is ‘sleeping with that fear’ that your competitor will steal your idea
By Preston ForeJune 13, 2026
2 days ago
Boomers actually do hold most of the wealth and power. So why do they call it 'whiny' to point that out?
Economy
Boomers actually do hold most of the wealth and power. So why do they call it 'whiny' to point that out?
By Nick LichtenbergJune 14, 2026
21 hours ago
Iran proved it can close the Strait of Hormuz, but the U.S. is advertising very loudly that the world's top superpower can at least punch open a hole
Energy
Iran proved it can close the Strait of Hormuz, but the U.S. is advertising very loudly that the world's top superpower can at least punch open a hole
By Jason MaJune 14, 2026
14 hours ago
The Gen Z cofounder of $1.6 billion Whop says his platform has minted over 650 millionaires—he wants to make work fun and money worries obsolete
Success
The Gen Z cofounder of $1.6 billion Whop says his platform has minted over 650 millionaires—he wants to make work fun and money worries obsolete
By Emma BurleighJune 14, 2026
22 hours ago
SpaceX surge further boosts Saudi billionaire prince’s fortune
Investing
SpaceX surge further boosts Saudi billionaire prince’s fortune
By Adveith Nair and BloombergJune 14, 2026
17 hours ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.